drugset
drugset / Trial / NCT00796861

Trial of Sunitinib for Refractory Malignant Ascites

NCT00796861 ↗

Phase 2 Terminated 4 enrolled Milton S. Hershey Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.

Timeline

Start
2007-05
Primary completion
2011-04
Completion
2011-04

Outcome

Outcome not reported

Stopped (Enrollment): “Phycisican decided to terminate study due to slow patient accrual.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunitinib Small molecule 50 mg Oral

Indications

No indication recorded.